Fundraising Fox

Osteal Therapeutics

Dallas, US · Delaware corporation · 55 employees on LinkedIn · 3 known investors

Biotech

Founders & leadership

DT
David ThompsonExecutive
BD
Brian de BeaubienNamed on SEC filing
RR
Renee RyanNamed on SEC filing
JP
Jude PaganelliNamed on SEC filing

Board

MS
Martin SandsBoard director
JC
Judson CooperBoard director
BM
Biren MehtaBoard director
DC
David CashBoard director
RL
Rushu LuoBoard director
EO
Erik OrosBoard director
SP
Sonal PatelBoard director
DK
Douglas KohrsBoard director

Investors · 3

HM Venture PartnersSan Francisco

Also in the syndicate · 2

Johnson & Johnson InnovationZimmer Biometlead

Reported raises · per SEC filings

Form D private placements

$127.5M disclosed across 6 rounds · 2018–2025

▶$15.6MraisedNov 2025 · 10 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Martin SandsDirector
  • Judson CooperDirector
  • Brian de BeaubienExecutive Officer, Director
  • David ThompsonExecutive Officer, Director
  • Biren MehtaDirector
  • Douglas KohrsDirector
  • David CashDirector
  • Rushu LuoDirector
  • Erik OrosDirector
  • Sonal PatelDirector
Offering amount
$26.7M
Amount sold
$15.6M
First sale
Oct 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$50MraisedJun 2024 · 16 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Biren MehtaDirector
  • Rushu LuoDirector
  • David CashDirector
  • David ThompsonExecutive Officer, Director
  • Sonal PatelDirector
  • Brian de BeaubienDirector
  • Martin SandsDirector
  • Judson CooperDirector
  • Douglas KohrsDirector
Offering amount
$50M
Amount sold
$50M
First sale
May 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$22.3MraisedSep 2023 · 19 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Martin SandsDirector
  • Judson CooperDirector
  • David CashDirector
  • Biren MehtaDirector
  • David ThompsonExecutive Officer, Director
  • Rushu LuoDirector
  • Brian de BeaubienDirector
  • Douglas KohrsDirector
Offering amount
$23M
Amount sold
$22.3M
First sale
Aug 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$30.2MraisedDec 2021 · 59 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Douglas KohrsDirector
  • David CashDirector
  • Brian de BeaubienDirector
  • David ThompsonExecutive Officer, Director
  • Judson CooperDirector
  • Noam KrantzDirector
  • Rushu LuoDirector
Offering amount
$32.4M
Amount sold
$30.2M
First sale
Dec 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedJan 2021 · 25 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Noam KrantzDirector
  • Jude PaganelliExecutive Officer, Director
  • David CashDirector
  • Brian de BeaubienDirector
  • Douglas KohrsDirector
  • David ThompsonExecutive Officer, Director
Offering amount
$2M
Amount sold
$2M
First sale
Nov 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$7.4MraisedApr 2018 · 45 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Douglas KohrsDirector
  • Brian de BeaubienDirector
  • Renee RyanDirector
  • Jude PaganelliExecutive Officer, Director
Offering amount
$7.8M
Amount sold
$7.4M
First sale
Mar 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Sell or Invest in Osteal Therapeutics Stock Pre-IPOnasdaqprivatemarket.com · Oct 2025Osteal Therapeutics Secures $50M in Series D Financing | Orthopedic Design & Technologyodtmag.com · Aug 2024Funding Drought Over? Osteal Secures $50M to Tackle Joint Infections -orthostreams.com · Jun 2024Osteal raises $50m to bring joint infection drug/device combo to market - Pharmaceutical Technologypharmaceutical-technology.com · Jun 2024BioNTX Names Osteal Therapeutics 2023 Rising Starfinance.yahoo.com · Sep 2023Osteal Therapeutics Closes $23M Series C Financingfinsmes.com · Sep 2023

Frequently asked questions

Who are Osteal Therapeutics's investors?
Osteal Therapeutics's investors include HM Venture Partners.
How much funding has Osteal Therapeutics raised?
Osteal Therapeutics has disclosed $127.5M raised across 6 rounds.
Where is Osteal Therapeutics headquartered?
Osteal Therapeutics is headquartered in Dallas, US.